Tag: Erik Lium

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

sarah JonasAnnouncement

CastleVax, a clinical stage vaccine platform company, has received a Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority (BARDA), to support the development of a next-generation, booster vaccine to protect against COVID-19 for years to come.

Mount Sinai Awarded $11.6 Million Grant to Launch Comprehensive Center for Surgical Innovation and Expand Mount Sinai BioDesign

sarah JonasAnnouncement

In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health System announced today the launch of the Comprehensive Center for Surgical Innovation (CCSI).

Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need

sarah JonasAnnouncement

The Mount Sinai Health System has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company.